TABLE 6B - NEW PROCEDURE CODES
Procedure Code	Description	O.R.	MDC	MS-DRG
00D00ZZ*	Extraction of Brain, Open Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
00D03ZZ*	Extraction of Brain, Percutaneous Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
00D04ZZ*	Extraction of Brain, Percutaneous Endoscopic Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
00D70ZZ*	Extraction of Cerebral Hemisphere, Open Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
00D73ZZ*	Extraction of Cerebral Hemisphere, Percutaneous Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
00D74ZZ*	Extraction of Cerebral Hemisphere, Percutaneous Endoscopic Approach	Y	01	023, 024, 025, 026, 027
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	955
""				981, 982, 983
02C03Z7*	Extirpation of Matter from Coronary Artery, One Artery, Orbital Atherectomy Technique, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02C13Z7*	Extirpation of Matter from Coronary Artery, Two Arteries, Orbital Atherectomy Technique, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02C23Z7*	Extirpation of Matter from Coronary Artery, Three Arteries, Orbital Atherectomy Technique, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02C33Z7*	Extirpation of Matter from Coronary Artery, Four or More Arteries, Orbital Atherectomy Technique, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02F03ZZ*	Fragmentation in Coronary Artery, One Artery, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02F13ZZ*	Fragmentation in Coronary Artery, Two Arteries, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02F23ZZ*	Fragmentation in Coronary Artery, Three Arteries, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02F33ZZ*	Fragmentation in Coronary Artery, Four or More Arteries, Percutaneous Approach	Y	05	231, 232, 246, 247, 248, 249, 250, 251
""				981, 982, 983
02RA0LZ*	Replacement of Heart with Biologic and Synthetic Substitute, Autoregulated Electrohydraulic, Open Approach	Y	PRE	001, 002
02RA0MZ*	Replacement of Heart with Synthetic Substitute, Pneumatic, Open Approach	Y	PRE	001, 002
02RH38L*	Replacement of Pulmonary Valve with Zooplastic Tissue, In Existing Conduit, Percutaneous Approach	Y	05	266, 267
""				981, 982, 983
02RH38M*	Replacement of Pulmonary Valve with Zooplastic Tissue, Native Site, Percutaneous Approach	Y	05	266, 267
""				981, 982, 983
02VL0CZ	Restriction of Left Ventricle with Extraluminal Device, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL0DZ	Restriction of Left Ventricle with Intraluminal Device, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL0ZZ	Restriction of Left Ventricle, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL3CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Approach	Y	05	273, 274
""			21	907, 908, 909
""				981, 982, 983
02VL3DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL3ZZ	Restriction of Left Ventricle, Percutaneous Approach	Y	05	273, 274
""			21	907, 908, 909
""				981, 982, 983
02VL4CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL4DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL4ZZ	Restriction of Left Ventricle, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
03173ZF	Bypass Right Brachial Artery to Lower Arm Vein, Percutaneous Approach	Y	05	264
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
03183ZF	Bypass Left Brachial Artery to Lower Arm Vein, Percutaneous Approach	Y	05	264
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
03FG3Z0*	Fragmentation of Intracranial Artery, Percutaneous Approach, Ultrasonic	Y	05	252, 253, 254
""				987, 988, 989
03FG3ZZ*	Fragmentation of Intracranial Artery, Percutaneous Approach	Y	05	252, 253, 254
""				987, 988, 989
06LY7CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY7DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY7ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
07DT0ZX	Extraction of Bone Marrow, Open Approach, Diagnostic	N		
07DT0ZZ	Extraction of Bone Marrow, Open Approach	N		
07DT3ZX	Extraction of Bone Marrow, Percutaneous Approach, Diagnostic	N		
07DT3ZZ	Extraction of Bone Marrow, Percutaneous Approach	N		
0F800ZZ	Division of Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F803ZZ	Division of Liver, Percutaneous Approach	N		
0F804ZZ	Division of Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F810ZZ	Division of Right Lobe Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F813ZZ	Division of Right Lobe Liver, Percutaneous Approach	N		
0F814ZZ	Division of Right Lobe Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F820ZZ	Division of Left Lobe Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F823ZZ	Division of Left Lobe Liver, Percutaneous Approach	N		
0F824ZZ	Division of Left Lobe Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0K847ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening	Y	03	143, 144, 145
""			06	326, 327, 328
""				987, 988, 989
0K848ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening Endoscopic	Y	03	143, 144, 145
""			06	326, 327, 328
""				987, 988, 989
0NH003Z	Insertion of Infusion Device into Skull, Open Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0NH033Z	Insertion of Infusion Device into Skull, Percutaneous Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0NH043Z	Insertion of Infusion Device into Skull, Percutaneous Endoscopic Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0PS403Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0PS443Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0QBN0Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBN3Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBN4Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP0Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP3Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP4Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QS003Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0QS043Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0RPJ0J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ0J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ3J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ3J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ4J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ4J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK0J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK0J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK3J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK3J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK4J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK4J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ0J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ0J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ3J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ3J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ4J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ4J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJXJ6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, External Approach	N		
0RWJXJ7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, External Approach	N		
0RWK0J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK0J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK3J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK3J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK4J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK4J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWKXJ6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, External Approach	N		
0RWKXJ7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, External Approach	N		
30233D1*	Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Peripheral Vein, Percutaneous Approach	N		
30243D1*	Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Central Vein, Percutaneous Approach	N		
3E1M48X*	Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach, Diagnostic	N		
3E1M48Z*	Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach	N		
4B00XW0*	Measurement of Central Nervous Cerebrospinal Fluid Shunt using Wireless Sensor, External Approach	N		
5A1221J	Performance of Cardiac Output, Continuous, Automated	N		
BF150ZZ	Fluoroscopy of Liver using High Osmolar Contrast	N		
BF151ZZ	Fluoroscopy of Liver using Low Osmolar Contrast	N		
BF15YZZ	Fluoroscopy of Liver using Other Contrast	N		
BF15ZZA	Fluoroscopy of Liver, Guidance	N		
X2CP3T7*	Extirpation of Matter from Abdominal Aorta using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	05	268, 269
""			06	356, 357, 358
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2CQ3T7*	Extirpation of Matter from Right Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	04	163, 164, 165
""			05	270, 271, 272
""				981, 982, 983
X2CR3T7*	Extirpation of Matter from Left Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	04	163, 164, 165
""			05	270, 271, 272
""				981, 982, 983
X2CS3T7*	Extirpation of Matter from Right Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	05	270, 271, 272
""			06	356, 357, 358
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2CT3T7*	Extirpation of Matter from Left Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	05	270, 271, 272
""			06	356, 357, 358
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2CU3T7*	Extirpation of Matter from Right Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	05	270, 271, 272
""				981, 982, 983
X2CV3T7*	Extirpation of Matter from Left Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	05	270, 271, 272
""				981, 982, 983
X2CY3T7*	Extirpation of Matter from Great Vessel using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7	Y	04	163, 164, 165
""			05	270, 271, 272
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2JAX47*	Inspection of Heart using Transthoracic Echocardiography, Computer-aided Guidance, New Technology Group 7	N		
X2KB317*	Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7	Y	05	264
""			06	356, 357, 358
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2KC317*	Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7	Y	05	264
""			06	356, 357, 358
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2RX0N7*	Replacement of Thoracic Aorta, Arch using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7	Y	04	163, 164, 165
""			05	216, 217, 218, 219, 220, 221
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2V73Q7	Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7	Y	05	228, 229
""				981, 982, 983
X2VW0N7*	Restriction of Thoracic Aorta, Descending using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7	Y	05	216, 217, 218, 219, 220, 221
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XD2G4V7*	Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7	N		
XD2G8V7*	Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7	N		
XD2H4V7*	Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7	N		
XD2H8V7*	Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7	N		
XDPH8K7*	Irrigation of Lower GI using Intraoperative Single-use Oversleeve, Via Natural or Artificial Opening Endoscopic, New Technology Group 7	N		
XFJB8A7*	Inspection of Hepatobiliary Duct using Single-use Duodenoscope, New Technology Group 7	N		
XFJD8A7*	Inspection of Pancreatic Duct using Single-use Duodenoscope, New Technology Group 7	N		
XHRPXF7*	Replacement of Skin with Bioengineered Allogeneic Construct, External Approach, New Technology Group 7	Y	01	040, 041, 042
""			03	143, 144, 145
""			05	264
""			08	463, 464, 465
""			09	573, 574, 575, 576, 577, 578
""			10	622, 623, 624
""			21	904, 905
""			22	927, 928, 929
""			24	957, 958, 959
""				981, 982, 983
XNS00C7*	Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XNS03C7*	Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XNS40C7*	Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XNS43C7*	Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGA0R7*	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGA3R7*	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGA4R7*	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGB0R7*	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGB3R7*	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGB4R7*	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGC0R7*	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGC3R7*	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGC4R7*	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGD0R7*	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGD3R7*	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGD4R7*	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7	Y	01	028, 029, 030
""			08	453, 454, 455, 456, 457, 458, 459, 460
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XW00X27*	Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7	N		
XW01397*	Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7	N		
XW013H6	Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013K6	Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6	N(1)	
XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6	N(1)
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6	N(1)
XW01X27*	Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7	N		
XW03357	Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW03367	Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW03377*	Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW03387*	Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW033A7*	Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**(2)	PRE	018	
XW033B7*	Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW033C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033G6	Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033H6	Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033J7	Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033L7	Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW04357	Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW04367	Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW04377*	Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW04387*	Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW043A7*	Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7	N**(2)	PRE	018	
XW043B7*	Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW043C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043H6	Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043J7	Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043L7	Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW0V0P7	Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7	N		
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	N(1)
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	N(1)
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	N(1)
XW133D7*	Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW133E7*	Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW143D7*	Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW143E7*	Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XWHD7Q7*	Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7	N		
XXE0X07*	Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7	N		
XXE3X27*	Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7	N		
XXE5XR7*	Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7	N		
XXE5XT7*	Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7	N		
XXE5XV7*	Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7	N		
XXE97U7*	Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7	N		
XY0YX37*	Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7	N		

	Notes:
	(*)-These codes were discussed at the March 9, 2021 - March 10, 2021 ICD-10 Coordination and Maintenance Committee meeting and were not finalized in time to include in the proposed rule. They will be implemented on October 1, 2021.
	(**)-Non-OR procedure affects DRGs
	(1)-Implemented January 1, 2021
	(2)-Effective beginning April 1, 2022
